<DOC>
	<DOC>NCT01312311</DOC>
	<brief_summary>The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer</brief_summary>
	<brief_title>Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>histologically confirmed nasopharyngeal cancer chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment) ECOG 01 at least one measurable lesion other cancer pregnat docetaxel hypersentitivity history severe heart or pulmonary disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>nasopharyngeal cancer</keyword>
	<keyword>weekly docetaxel</keyword>
	<keyword>cisplatin</keyword>
</DOC>